Skip to content

Study · Case report or series · n = 1 · 2024

3 results

Semaglutide Inducing Resolution of Proliferative Diabetic Retinopathy: A Case Report.

Cool D, Coventon J, Sharma A

Case reports in ophthalmological medicine10 Dec 2024Cited by 4 (Europe PMC)

PMID39691771 (opens in a new tab)PMCIDPMC11651726 (opens in a new tab)DOI10.1155/crop/5834769 (opens in a new tab)PepBankPUB-39691771
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Purpose: To describe a case of regression of proliferative diabetic retinopathy (PDR) following treatment with semaglutide. Methods: Case report. Results: The case describes a 47-year-old woman with Type 2 diabetes, obesity, hypertension, and dyslipidaemia who had difficulty controlling her blood sugar levels despite oral hypoglycaemic medications. She presented with PDR in her right eye and severe nonproliferative diabetic retinopathy (NPDR) in her left eye. After missing her follow-up appointment for panretinal photocoagulation (PRP), her general practitioner initiated semaglutide therapy. Despite minimal changes in glycaemic control, the patient exhibited resolution of neovascularisation in her right eye and improved diabetic macular oedema (DMO) within 6 weeks of semaglutide therapy. Conclusion: This case report suggests a potential independent role for semaglutide in managing PDR.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with type 2 diabetes and proliferative diabetic retinopathy, neovascularisation in the right eye resolved within 6 weeks of semaglutide therapy.

    In plain wordsIn one woman with type 2 diabetes, abnormal eye vessels in her right eye went away within 6 weeks of starting semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseNeovascularisation in proliferative diabetic retinopathy
    Study

    n = 1

    Outcome group
    Vision and retina · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Despite minimal changes in glycaemic control, the patient exhibited resolution of neovascularisation in her right eye and improved diabetic macular oedema (DMO) within 6 weeks of semaglutide therapy.
    2 context sentences
    Summary · context
    The case describes a 47-year-old woman with Type 2 diabetes, obesity, hypertension, and dyslipidaemia who had difficulty controlling her blood sugar levels despite oral hypoglycaemic medications.
    Summary · context
    After missing her follow-up appointment for panretinal photocoagulation (PRP), her general practitioner initiated semaglutide therapy.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with type 2 diabetes and proliferative diabetic retinopathy, diabetic macular oedema improved within 6 weeks of semaglutide therapy.

    In plain wordsIn one woman with type 2 diabetes, swelling in the back of her eye improved within 6 weeks of starting semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseDiabetic macular oedema
    Study

    n = 1

    Outcome group
    Vision and retina · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Despite minimal changes in glycaemic control, the patient exhibited resolution of neovascularisation in her right eye and improved diabetic macular oedema (DMO) within 6 weeks of semaglutide therapy.
    2 context sentences
    Summary · context
    The case describes a 47-year-old woman with Type 2 diabetes, obesity, hypertension, and dyslipidaemia who had difficulty controlling her blood sugar levels despite oral hypoglycaemic medications.
    Summary · context
    After missing her follow-up appointment for panretinal photocoagulation (PRP), her general practitioner initiated semaglutide therapy.
  3. 03HumanCase report or seriesEfficacy outcome

    In a woman with type 2 diabetes, glycaemic control changed minimally with semaglutide therapy.

    In plain wordsIn one woman with type 2 diabetes, blood sugar control changed little on semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeGlycaemic control
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Despite minimal changes in glycaemic control, the patient exhibited resolution of neovascularisation in her right eye and improved diabetic macular oedema (DMO) within 6 weeks of semaglutide therapy.
    2 context sentences
    Summary · context
    The case describes a 47-year-old woman with Type 2 diabetes, obesity, hypertension, and dyslipidaemia who had difficulty controlling her blood sugar levels despite oral hypoglycaemic medications.
    Summary · context
    After missing her follow-up appointment for panretinal photocoagulation (PRP), her general practitioner initiated semaglutide therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.